Lilly latone reduces cardiovascular events in people with type 2 diabetes
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Lilly announced that its weekly administration of polyglycin in the REWIND study showed that diglyglyceridesin significantly reduced major cardiovascular adverse events (MACE), that includecardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-lethal stroke compound endpointonly 31% of patients diagnosed with cardiovascular disease at baseline, meeting the key efficacy targets set in advance in the REWIND study, which is also the first clinical
trial(in which the drugdrug(of type 2 diabetes, which has been shown to benefit from improved MACE events, is largely in the clinicalof patients with undiagnosed cardiovascular diseaseon theof polyglutagin peptides in China has entered the drug review center priority review, has not been approved for listingstudiesmost of the patients included in the study had undiagnosed cardiovascular disease at baseline, the first study of cardiovascular outcomes of GLP-1 receptor agonistdrugsThe REWIND study assessed the risk of MACE events in adults with type 2 diabetes with various cardiovascular risksThe study compared the efficacy of 1.5 mg of the lactator peptide once a week with the effect of a placebo on the basis of standard treatmentThe safety of polyglycine in the REWIND study is similar to that of GLP-1 receptor agonist drugsLilly plans to submit the data to regulators next year and share detailed findings at the 2019 ADA ScienceConference
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
